Goserelin: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders

Drugs

Volumn 51, Issue 2, 1996, Pages 319-346

  Perry, Caroline M ^a   Brogden, Rex N ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; FOLLITROPIN; GONADOTROPIN; GOSERELIN; HYPOTHALAMUS RELEASING FACTOR; LUTEINIZING HORMONE;

BONE ATROPHY; DRUG EFFICACY; ENDOMETRIOSIS; ESTROGEN BLOOD LEVEL; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; INFERTILITY THERAPY; LIBIDO; MENOPAUSE; OVARIECTOMY; REVIEW; STEROIDOGENESIS; SYMPTOM; UTERUS BLEEDING; UTERUS DISEASE; UTERUS MYOMA;

EID: 0030065441     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199651020-00009     Document Type: Review

References (113)

1. Chrisp P, Goa KL. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties, and clinical use in sex hormone-related conditions. Drugs 1991 Feb; 41: 254-88
2. Maouris P, Dowsett MMG, Rose G, et al. The effect of danazol and the LHRH agonist analogue goserelin (Zoladex) on the biological activity of luteinizing hormone in women with endometriosis. Clin Endocrinol 1990 Oct; 33: 539-46
3. Garner C. Uses of GnRH agonists. J Obstet Gynecol Neonatal Nurs 1994 Sep; 23: 563-70
4. Filicori M. Gonadotrophin-releasing hormone agonists: a guide to use and selection. Drugs 1994; 48 (1): 41-58
5. Filicori M, Flamigni C. GnRH agonists and antagonists. Current clinical status. Drugs 1988; 35 (1): 63-82
6. Tapanainen JS, Hovatta O. Pituitary down-regulation with goserelin (Zoladex) for in vitro fertilisation. Br J Obstet Gynaecol 1994 May; 101 Suppl. 10: 27-8
7. Thomas EJ, Jenkins J, Lenton EA, et al. Endocrine effects of goserelin, a new depot luteinising hormone releasing hormone agonist. Br Med J Clin Res Ed 1986 Nov 29; 293: 1407-8
8. Matta WH, Shaw RW, Burford GD. Endocrinologic and clinical evaluation following a single administration of a gonadotrophin-releasing hormone agonist (Zoladex), in a depot formulation, to premenopausal women. Fertil Steril 1988 Jan; 49: 163-5
9. Ledger WL, Thomas EJ, Browning D, et al. Suppression of gonadotrophin secretion does not reverse premature ovarian failure [see comments]. Br J Obstet Gynaecol 1989 Feb; 96: 196-9
10. Shaw RW, editor. Advances in Reproductive Endocrinology. First ed. vol. 1; Endometriosis. Carnforth: Parthenon Publishing Group Limited, 1990
11. Lindoff C, Petersson F, Samsioe G, et al. Treatment with a GnRH analogue: effects on hemostatic risk factors for thrombo-embolic disease. Int J Fertil Menopausal Stud 1994 May-Jun; 39: 133-9
12. Lemay A, Brideau NA, Forest JC, et al. Cholesterol fractions and apolipoproteins during endometriosis treatment by a gonadotrophin releasing hormone (GnRH) agonist implant or by danazol. Clin Endocrinol Oxf 1991 Oct; 35: 305-10
13. Rossmanith WG, Wirth U, Sasse V, et al. Treatment with different GnRH analogues in women: preliminary evidence for disparant effects on serum androgen concentrations. Horm Metab Res 1991 Apr; 23: 198-9
14. Mettler L, Steinmuller H, Schachner-Wunschmann E. Experience with a depot gnRH-agonist (Zoladex) in the treatment of genital endometriosis. Hum Reprod 1991 May; 6: 694-8
15. West CP, Baird DT. Suppression of ovarian activity by Zoladex depot (ICI 118630), a long-acting luteinizing hormone releasing hormone agonist analogue. Clin Endocrinol Oxf 1987 Feb; 26: 213-20
16. Golland IM, Vaughan-Williams CA, Shalet SM, et al. Influence of danazol and goserelin on insulin and glucagon in non-obese women with endometriosis. Acta Endocrinol 1990 Oct; 123: 405-10
17. Baird DT, Bramley TA, Hawkins TA, et al. Effect of treatment with LHRH analogue Zoladex on binding of oestradiol, progesterone and epidermal growth factor to uterine fibromyomata. Horm Res 1989; 32 Suppl. 1: 154-6
18. Lumsden MA, West CP, Bramley T, et al. The binding of epidermal growth factor to the human uterus and leiomyomata in women rendered hypo-oestrogenic by continuous administration of an LHRH agonist. Br J Obstet Gynaecol 1988 Dec; 95: 1299-304
19. Crook D, Gardner R, Worthington M, et al. Zoladex versus danazol in the treatment of pelvic endometriosis: effects on plasma lipid risk factors. Horm Res 1989; 32 Suppl. 1: 157-60
20. Brogden RN, Faulds D. Goserelin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs 1995; 6 (4): 324-43
21. Filicori M, Flamigni C, Cognigni G, et al. Comparison of the suppressive capacity of different depot gonadotropin-releasing hormone analogs in women. J Clin Endocrinol Metab 1993 Jul; 77: 130-3
22. Leone M, Cucuccio S, Venturim PL, et al. Immunohistochemical localization of epidermal growth factor receptor in leiomyomas from women treated with goserelin depot. Horm Metab Res 1991 Sep; 23: 442-5
23. Shaw RW. Mechanism of LHRH analogue action in uterine fibroids. Horm Res 1989; 32 Suppl. 1: 150-3
24. Zeneca Pharmaceuticals, data on file, 1995.
25. Perren TJ, Claylon N, Blackledge G, et al. Pharmacokinetic and endocrinological parameters of a slow release depot preparation of the GnRH analogue ICI 118630 (Zoladex) compared with subcutaneous bolus and continuous subcutaneous infusion of the same drug in patients with prostatic cancer. Chemotherapy and Pharmacology 1986; 18: 39-43
26. 10 GnRH. Clin Endocrinol 1985; 22: 453-62
27. Ahmann FR, Citrin DL, de Haan HA, et al. Zoladez: a sustained release, monthly luteinizing hormone-releasing hormone analogue for the treatment of advanced prostate cancer. J Clin Oncol 1987; 5: 912-7
28. Kotake T, Usami M, Sonoda T, et al. Zoladex (goserelin) depot formulation in the treatment of prostatic cancer: randomised dose-II fiding trial in Japan. American Journal of Clinical Oncology - Cancer Clinical Trials 11 1988 Suppl. 2: 108-11
29. Adam HK, Barker Y, Hutchinson FG, et al. Zoladez: a one-month duration LH-RH agonist. Symposium on disposition and delivery of peptide drugs. Abstract no. 8964. Leiden, 1987 Sep 5-6. Pharmaceutisch Weekblad Scientific Edition 10: 57.
30. Adam HK. The importance of the pharmacokinetics of hormonal drugs in the therapy of prostatic carcinoma. Acta Urologica Italica 1991; (6) Suppl. 2: 9-17
31. Lemay A, Faure N. Sequential estrogen-progestin addition to gonadotropin-releasing hormone agonist suppression for the chronic treatment of ovarian hyperandrogenism, a pilot study. J Clin Endocrinol Metab 1994; 79: 1716-22
32. Tiitinen A, Simberg N, Stenman U-H, et al. Estrogen replacement does not potentiate gonadotropin-releasing hormone agonist-induced androgen suppression in treatment ot hirsutism. J Clin Endocrinol Metab 1994 Aug; 79: 447-51
33. Plosker GL, Brogden RN. Leuprorelin: a review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994; 48 (6): 930-67
34. Rock JA, Truglia JA, Caplan RJ, et al. Zoladex (goserelin acetate implant) in the treatment of endometriosis: a randomised comparison with danazol. Obstet Gynecol 1993 Aug; 82: 198-205
35. Moghissi KS. Gonadotropin releasing hormones: clinical applications in gynecology. J Reprod Med 1990; 35: 1097-107
36. Uemura T, Minaguchi H, Okuda K, et al. GnRH agonist Zoladex in the treatment of endometriosis [in Japanese]. Yakuri to Chiryo 1992 Sep: 20: 3823-37
37. Reichel RP, Schweppe KW. Goserelin (Zoladex) depot in the treatment of endometriosis. Zoladex Endometriosis Study Group. Fertil Steril 1992 Jun; 57: 1197-202
38. Venturini PL, Anserini P, Fasce V, et al. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results. Fertil Steril 1990 Dec; 54: 1021-7
39. Ivanov S. A study to assess the safety and efficacy of zoladex in the treatment of endometriosis [abstract]. Oncologia 1993; 30 Suppl. 1: 80
40. Schweppe K-W. Effect of GnRH-analogue treatment with a depot-preparation in patients with endometriosis [in German]. Med Welt 1994 May; 45: 183-8
41. Shaw RW. An open randomized comparative study of the effect of goserelin depot and danazol in the treatment of endometriosis. Fertil Steril 1992 Aug; 58: 265-72
42. Vercellini P, Trespidi L, Colombo A, et al. A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis. Fertil Steril 1993; 60: 75-9
43. Howell R, Edmonds DK, Dowsett M, et al. Gonadotropin-releasing hormone analogue (goserelin) plus hormone replacement therapy for the treatment of endometriosis: a randomized controlled trial. Fertil Steril 1995; 64 (3): 474-81
44. Kiilholma P, Tuimala R, Kivenen S, et al. Comparison of the gonadotropin-releasing hormone agonist goserelin acetate alone versus goserelin combined with estrogen-progestogen add-back therapy in the treatment of endometriosis. Fertil Steril 1995; 64 (5): 903-8
45. Schlaff WD, Moghissi K, Lemay A, et al. Multicenter trial comparing 3.6mg Zoladex therapy with or without hormone replacement therapy for the treatment of endometriosis [Abstract]. 51st Annual Meeting of the American Society for Reproductive Medicine 1995: S11-S12 Abstract 0-021, Seattle, USA, 7-12 Oct 1995
46. Magini A, Pellegrini S, Tavella K, et al. Estrogenic suppression by different administration schedules of goserelin depot for treatment of endometriosis. J Endocrinol Invest 1993 Nov; 16: 775-80
47. Mettler L. Pathogenesis, diagnosis and treatment of genital endometriosis. Acta Obstet Gynecol Scand 1990; 68 Suppl. 150: 31-7
48. Donnez J, Anaf V, Nisolle M, et al. Ovarian endometrial cysts: the role of gonadotropin-releasing hormone agonist and/or drainage. Fertil Steril 1994 Jul; 62: 63-6
49. Edmonds KD, Howell R. Can hormone replacement therapy be used during medical therapy of endometriosis? Br J Obstet Gynaecol 1994 May; 101 Suppl. 10: 24-6
50. Wingfield M, Healy DL. Endometriosis: medical therapy. Baillieres Clin Obstet Gynaecol 1993 Dec; 7: 813-38
51. Llewellyn-Jones D, editor. Fundamentals of obstetrics and gynaecology. 5th ed. vol. 2: Gynaecology. London: Faber and Faber, 1990
52. Friedman AJ, Lobel SM, Rein MS, et al. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: the estrogen threshold hypothesis. Am J Obstet Gynecol 1990 Oct; 163 (4 Pt 1): 1114-9
53. Audebert AJ, Madenelat P, Querleu D, et al. Deferred versus immediate surgery for uterine fibroids: clinical trial results. Br J Obstet Gynaecol 1994 May; 101 Suppl. 10: 29-32
54. Benagiano G, Kivenen ST, Mangioni C, et al. Zoladex® (goserelin acetate) and the anemic patient. Results of a multicenter fibroid study. Zeneca Pharmaceuticals, 1995: Data on file.
55. Gerris J, Degueldre M, Peters AAW, et al. The place of Zoladex in deferred surgery for uterine fibroids. Horm Res. In press
56. Lumsden MA, West CP, Thomas E, et al. Treatment with the gonadotrophin releasing hormone-agonist goserelin before hysterectomy for uterine fibroids. Br J Obstet Gynaecol 1994 May; 101: 438-42
57. McClelland HR, Quinn AJ. Shrinkage of uterine fibroids by preoperative LHRH analogue injection. Ulster Med J 1992 Apr; 61: 51-5
58. Vercellini P, Bocciolone L, Colombo A, et al. Gonadotropin releasing hormone agonist treatment before hysterectomy for menorrhagia and uterine leiomyomas. Acta Obstet Gynecol Scand 1993 Jul; 72: 369-73
59. Cagnacci A, Paoletli AM, Soldani R, et al. Role of goserelin-depot in the clinical management of uterine fibroids. Clin Exp Obstet Gynecol 1994; 21: 263-5
60. Maheux R, Lemay A, Blanchet P, et al. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study. Hum Reprod 1991 Apr; 6: 500-5
61. Maheux R. A multicenter randomized comparison of endocrine effects, pharmacokinetics, efficacy and safety of 3.6 mg vs 7.2 mg goserelin acetate (Zoladex® implant) in the treatment of uterine leiomyoma [abstract]. Fertil Steril 1991 Oct 21-24; Program Suppl. 1991: S127
62. Costantini S, Anserini P, Valenzano M, et al. Luteinizing hormone-releasing hormone analog therapy of uterine fibroid: analysis of results obtained with buserelin administered intranasally and goserelin administered subcutaneously as a monthly depot. Eur J Obstet Gynecol Reprod Biol 1990 Oct; 37: 63-9
63. Hackenberg R, Gesenhues T, Deichen U, et al. Preoperative reduction of myomas of the uterus by the GnRH-analogue goserelin (Zoladex) [in German]. Geburtshilfe Frauenheilkd 1990 Feb; 50: 136-9
64. Pretreatment with Zoladex improves surgery for uterine fibroids [news]. Oncology Huntingt 1991 Jan; 5: 94
65. West CP, Lumsden MA, Baird DT. Goserelin (Zoladex®) in the treatment of fibroids. Br J Obstet Gynaecol 1992 Feb; 99 Suppl. 7: 27-30
66. Candiani GB, Vercellini P, Fedele L, et al. Use of goserelin depot, a gonadotropin-releasing hormone agonist, for the treatment of menorrhagia and severe anemia in women with leiomyomata uteri. Acta Obstet Gynecol Scand 1990; 69 (5): 413-5
67. Donnez J, Gillerot S, Bourgonjon D. et al. Neodymium: YAG laser hysteroscopy in large submucous fibroids. Fertil Steril 1990; 54 (6): 999-1003
68. Giorgino FL, Cetera C. The management of leiomyoma uteri by GnRH analogues. Clin Exp Obstet Gynecol 1991; 18: 137-43
69. Hackenberg R, Gesenhues T, Deichen U, et al. The response of uterine fibroids to GnRH-agonist treatment can be predicted in most cases after one month. Eur J Obstet Gynecol Reprod Biol 1992 Jul 3; 45: 125-9
70. Alfini P, Bianco V, Felice R, et al. Treatment of uterine fibroma with goserelin [in Italian]. Ann Ostet Ginecol Med Perinat 1991 Nov-Dec; 112: 359-67
71. West CP, Lumsden MA, Lawson S, et al. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot. Fertil Steril 1987 Jul; 48: 45-51
72. Vercellini P, Vendola N, Colombo A, et al. Goserelin versus danazol for the treatment of menorrhagia associated with submucous myomas [abstract]. Fertil Steril 1992: 81
73. Lumsden MA, West CP, Baird DT. Goserelin therapy before surgery for uterine fibroids [letter]. Lancet 1987 Jan 3; 1: 36-7
74. Maheux R, Lemay A. Treatment of peri-menopausal women: potential long-term therapy with a depot GnRH agonist combined with hormonal replacement therapy. Br J Obstet Gynaecol 1992 Feb; 99 Suppl. 7: 13-7
75. Maheux R. Treatment of fibroids with the combination of the GnRH agonist goserelin (Zoladex) and hormone replacement therapy. Advances in Reproductive Endocrinology 1992; 4: 135-46
76. Thomas EJ, Okuda KJ, Thomas NM. The combination of a depot gonadotrophin releasing hormone agonist and cyclical hormone replacement therapy for dysfunctional uterine bleeding. Br J Obstet Gynaecol 1991 Nov; 98: 1155-9
77. Zoladex for endometrial thinning. Scrip 1995 Jul 14; 2042: 21
78. Bulletti C, Flumigni C, Prefetto RA, et al. Dysfunctional uterine bleeding (DUB). Ann N Y Acad Sci 1994 Sep 30; 734: 80-90
79. Donnez J, Nisolle M, Clerckx F, et al. Advanced endoscopic techniques used in dysfunctional bleeding, fibroids and endometriosis, and the role of gonadotrophin-releasing hormone agonist treatment. Br J Obstet Gynaecol 1994 May; 101 Suppl. 10: 2-9
80. Crosignani PG, Vercellini P, Perino A, et al. Treatment with a gonadotropin releasing hormone agonist (GnRH-a) before trans-cervical resection of the endometrium (TCRE): a randomized multicenter study. Zeneca Pharmaceuticals 1994; Data on file.
81. Thijssen RFA, Rolland R. Radiofrequency endometrial ablation and GnRH analogue pretreatment. Gynaecological Endoscopy 1995; 4 (1): 49-52
82. Stampe Sørenson S, Vejerslev LO, Palmgren CN. Depot-GnRH analogue pre- and posttreatment in endometrial ablation [abstract no. 60]. Acta Obstet Gynecol Scand 1994; 73 Suppl. 161
83. Vercellini P, Trespidi L, Bramante T, et al. Gonadotropin releasing hormone agonist treatment before hysteroscopic endometrial resection. Int J Gynecol Obstet 1994 Jun; 45: 235-9
84. Vercellini P, Fedele L, Maggi R, et al. Gonadotropin releasing hormone agonist for chronic anovulatory uterine bleeding and severe anemia. J Reprod Med 1993 Feb; 38: 127-9
85. Garry R, Khair A, Mooney P, et al. A comparison of goserelin and danazol as endometrial thinning agents prior to endometrial laser ablation. Br J Obstet Gynaecol. In press
86. Sutton CJ, Ewen SP. Thinning the endometrium prior to ablation: is it worthwhile? Br J Obstet Gynaecol 1994 May; 101 Suppl. 10 10-2
87. Fraser IS, Healy DlL, Torode H, et al. Goserelin implant and danazol pretreatment before roller-ball endometrial ablation for menorrhagia. Obstet Gynaecol. In press
88. Gangar KP, Stones RW, Saunders D, et al. An alternative to hysterectomy? GnRH analogue combined with hormone replacement therapy. Br J Obstet Gynaecol 1993 Apr; 100: 360-4
89. Choice of gonadorelin agonist for a given indication depends on the formulation. Drug Ther Perspect 1995 Jul 24; 6 (2): 1-4
90. Tapanainen J, Hovatta O, Juntunen K, et al. Subcutaneous goserelin versus intranasal buserelin for pituitary down-regulation in patients undergoing IVF - a randomized comparative study. Hum Reprod 1993 Dec; 8: 2052-5
91. DeSutter P, Dhont M, Vandekerckhove D. Hormonal stimulation for in vitro fertilization: a comparison of fertilization rates and cytogenetic findings in unfertilized oocytes. J Assist Reprod Genet 1992 Jun; 9: 254-8
92. Gerli S, Villani C. Endocrine changes and follicular development in patients during ovulation induction using Goserelin and different gonadotropin treatments. Clin Exp Obstet Gynecol 1993; 20: 245-50
93. Macrow PJ, Li TC, Seif MW, et al. Endometrial structure after superovulation: a prospective controlled study [see comments]. Fertil Steril 1994 Apr; 61: 696-9
94. Craft I, Ah-Moye M, Al-Shawaf T, et al. Analysis of 1071 gift procedures - the case for a flexible approach to treatment. Lancet 1988 May 14: 1094-8
95. Vauthier D, Lefebvre G, Brouzes D. Use of goserelin (Zoladex) for a long protocol of ovarian stimulation in an IVF program. Advances in the study of GnRH analogues 1992; 3: 53-54.
96. Dhont M, Onghena A, Coetsier T, et al. Prospective randomised study of clomiphene citrate and gonadotrophins versus goserelin and gonadotrophins for follicular stimulation in assisted reproduction. Hum Reprod 1995; 10 (4): 791-6
97. De Vita V. Bromocriptine + gonadotropin vs. goserelin + gonadotropin in ovulation induction in patients with polycystic ovaries. Minerva Ginecol 1995 Mar; 47 (3): 93-7
98. Dawood MY. Hormonal therapies for endometriosis: implications for bone metabolism. Acta Obstet Gynecol Scand 1994; 73 Suppl. 159: 22-34
99. Vercellini P, Vendola N, Colombo A, et al. Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest 1992; 34 (2): 102-4
100. Miller RM, Frank RA. Zoladex® (goserelini), in the treatment of benign gynaecological disorders: an overview of safety and efficacy. Br J Obstet Gynaecol 1992 Feb; 99 Suppl. 7: 37-41
101. Leather AT, Studd JWW, Watson NR, et al. The prevention of bone loss in young women treated with GnRH analogues with 'add-back' estrogen therapy. Obstet Gynecol 1993 Jan; 81: 104-7
102. Fogelman I, Fentiman I, Hamed H, et al. Goserelin (Zoladex) and the skeleton. Br J Obstet Gynaecol 1994 May; 101 Suppl. 10: 19-23
103. Dodin S, Lemay A, Maheux R, et al. Bone mass in endometriosis patients treated with GnRH agonist implant or danazol. Obstet Gynecol 1991 Mar; 77: 410-5
104. Van Leusden HAIM. Impact of different GnRH analogs in benign gynecological disorders related to their chemical structure, delivery systems and dose. Gynecol Endocrinol 1994 Sep; 8: 215-22
105. Dawood MY. Considerations in selecting appropriate medical therapy for endometriosis. Int J Gynecol Obstet 1993; 40 Suppl.: S29-42
106. Dawood MY. Impact of medical treatment of endometriosis on bone mass. Am J Obstet Gynecol 1993; 168: 674-84
107. Fedele L, Zanotti F, Marchini M, et al. Is bone loss induced by gonadotropin releasing hormone agonist treatment really reversible? [abstract]. Fertil Steril 1993: S70-1
108. Stevenson JC, Lees B, Gardner R, et al. A comparison of the skeletal effects of goserelin and danazol in premenopausal women with endometriosis. Horm Res 1989; 32 Suppl. 1: 161-4
109. Simberg N, Tiitinen A, Ylikorkala O. Estrogen add back-therapy prevents bone loss in women with ovarian hirsutism treated with a long acting GnRH agonist (Zoladex depot) [abstract]. Fertil Steril 1993: 52
110. Kang IS, Kuehl TJ, Siler-Khodr TM. Effect of treatment with gonadotropin-releasing hormone analogues on pregnancy outcome in the baboon. Fertil Steril 1989 Nov; 52: 846-53
111. Pickersgill A, Kingsland CR, Garden AS, et al. Multiple gestation following gonadotrophin releasing hormone therapy for the treatment of minimal endometriosis. Br J Obstet Gynaecol 1994 Mar; 101: 260-2
112. Zeneca Pharma. Goserelin prescribing information. ABPI Data Sheet Compendium. Datapharm Publications Ltd, United Kingdom, 1994-95
113. Reid BA, Gangar KF, Beard RW. Severe endometriosis treated with gonadotrophin releasing hormone agonist and continuous combined hormone replacement therapy. Br J Obstet Gynaecol 1992 Apr; 99: 344-5